Sanofi stock drop over 10% after Amlitelimab Phase III results raises concerns about future pipeline and Dupixent patent expiration.
Author: PharmaSignal News Desk
Avadel XWPharma partnership secures global rights to valiloxybate, targeting narcolepsy and idiopathic hypersomnia.
FDA rejection letters will be released soon after issuance, enhancing transparency in the drug review process.
WHO essential medicines list now includes cancer and diabetes drugs, adding 20 new medicines for adults and 15 for children.
Enlaza Vertex collaboration forms a $2.4 billion deal to advance autoimmune therapies using War-Lock technology.
Servier Fragile X acquisition involves KER-0193, enhancing its neurology pipeline with a $450m deal.
FDA foreign inspections increase, targeting drug manufacturers without notice, as Commissioner Makary outlines new strategy.
Novartis Tourmaline Bio acquisition for $1.4bn expands its cardiovascular portfolio with pacibekitug.
Merck ADC lung cancer treatment shows nearly 50% tumor shrinkage in mid-stage trial, heading to FDA.
Amneal FDA warning highlights use of contaminated bags in sterile injectable drugs, impacting quality control.